GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arch Therapeutics Inc (OTCPK:ARTH) » Definitions » PB Ratio
中文

Arch Therapeutics (Arch Therapeutics) PB Ratio : (As of Apr. 24, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Arch Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-24), Arch Therapeutics's share price is $1.18. Arch Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was $-2.02. Hence, Arch Therapeutics's PB Ratio of today is .

The historical rank and industry rank for Arch Therapeutics's PB Ratio or its related term are showing as below:

During the past 13 years, Arch Therapeutics's highest PB Ratio was 44.23. The lowest was 11.01. And the median was 21.00.

ARTH's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.38
* Ranked among companies with meaningful PB Ratio only.

During the past 3 years, the average Book Value Per Share Growth Rate was -1.00% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Arch Therapeutics was 95.20% per year. The lowest was -53.40% per year. And the median was -8.85% per year.

Back to Basics: PB Ratio


Arch Therapeutics PB Ratio Historical Data

The historical data trend for Arch Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arch Therapeutics PB Ratio Chart

Arch Therapeutics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Arch Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Arch Therapeutics's PB Ratio

For the Biotechnology subindustry, Arch Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arch Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arch Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Arch Therapeutics's PB Ratio falls into.



Arch Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Arch Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=1.18/-2.019
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Arch Therapeutics  (OTCPK:ARTH) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Arch Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Arch Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Arch Therapeutics (Arch Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
235 Walnut Street, Suite 6, Framingham, MA, USA, 01702
Arch Therapeutics Inc is a development-stage biotechnology company. It focuses on developing products that manage surgery and interventional care faster and safer by using a novel approach to stop bleeding, control leaking, and provide other advantages during surgery and trauma care. The company's primary product candidate, collectively known as the AC5 Devices (AC5), is designed to achieve hemostasis in surgical procedures. The company operates its business operations in the United States.
Executives
Terrence W Norchi director, officer: President & CEO C/O ARCH THERAPEUTICS, INC., PO BOX 748, NATICK MA 01760
Michael S Abrams officer: CFO and Treasurer 64 RAMSHEAD ROAD, RAYNHAM MA 02767
Laurence Hicks director C/O ARCH THERAPEUTICS, INC., 235 WALNUT STREET, SUITE 6, FRAMINGHAM MA 01702
Guy L. Fish director C/O ARCH THERAPEUTICS, INC., 235 WALNUT STREET, SUITE 6, FRAMINGHAM MA 01702
Dan Yrigoyen officer: Vice President, Sales C/O ARCH THERAPEUTICS, INC., 235 WALNUT STREET, SUITE 6, FRAMINGHAM MA 01702
James R Sulat director
Punit Dhillon director 5820 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Richard E Davis officer: CFO & Treasurer
Avtar S Dhillon director C/O GENETRONICS INC, 11199 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Arthur L Rosenthal director 100 CYBERONICS BLVD., HOUSTON TX 77058
Alan Barber officer: Chief Financial Officer C/O ARCH THERAPEUTICS, INC., PO BOX 748, NATICK MA 01760
William M Cotter officer: Chief Operating Officer C/O CLOSURE MEDICAL CORP, 5250 GREEN DAIRY RD, RALEIGH NC 27616

Arch Therapeutics (Arch Therapeutics) Headlines

From GuruFocus